EGFR and non-small cell lung carcinoma: The advent of the prototypic third-generation EGFR TKI, osimertinib, which is highly selective for both activating EGFR and T790M resistance mutations, offers further advantages to non–small cell lung cancer (NSCLC) patients with de novo or acquired T790M mutations [10–12].